Ciphergen Q1 Revenues Jump 80 Percent | GenomeWeb

NEW YORK, May 1 – Ciphergen Biosystems reported Tuesday an 80 percent increase in first-quarter revenues to $2.7 million from $1.5 million in the year-ago quarter.

The company attributed the increase to greater sales of its ProteinChip systems and arrays in addition to service revenue from their Biomarker Discovery Centers. The growth represents “continued progress in our mission of enabling benchtop biologists to perform proteomics research," William Rich, CEO of Ciphergen, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.